methyl 4-<<6-amino>indol-1-yl>methyl>-3-methoxybenzoate | 104435-96-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-<<6-amino>indol-1-yl>methyl>-3-methoxybenzoate
• 英文别名: methyl 4-<<6-<<(cyclopentyloxy)carbonyl>amino>indol-1-yl>methyl>-3-methoxybenzoate；methyl 4-[(6-{[(cyclopentyloxy)carbonyl]amino}indol-1-yl)methyl]-3-methoxybenzoate；Methyl 4-[[6-(cyclopentyloxycarbonylamino)indol-1-yl]methyl]-3-methoxybenzoate
• CAS: 104435-96-3
• 化学式: C₂₄H₂₆N₂O₅
• 分子量: 422.481
• InChiKey: INMOPPDOZQLSDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 4-<<6-amino>indol-1-yl>methyl>-3-methoxybenzoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 30.0h， 生成 4-[6-(环戊氧基-羰基)氨基吲哚-1-基甲基]-3-甲氧基苯甲酸
  参考文献：
  名称：

  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles

  摘要：

  A perception of structural similarities between two independent series of leukotriene antagonists (one emanating from FPL 55712 and one based upon the leukotrienes themselves) led to the discovery of a novel class of indole and indazole derived antagonists of peptidoleukotrienes. A systematic exploration of C-6 substituted 4-(indol-1-ylmethyl)-3-methoxybenzoic acids identified cyclopentylacetamide and cyclopentylurethane as preferred substituents. The corresponding indazoles were equipotent. These compounds are selective leukotriene antagonists with pKB values of 7.5-7.8 vs LTE4 on guinea pig trachea.

  DOI：

  10.1021/jm00168a036
• 作为产物：
  描述：

  3-甲氧基-4-甲基苯甲酸 在 palladium on activated charcoal 氢气 、 溴 、 potassium carbonate 、 溶剂黄146 、 乙酸乙酯 、 三乙胺 、 乙酰氯 作用下， 以 四氯化碳 、 丙酮 为溶剂， 25.0~80.0 ℃ 、344.73 kPa 条件下， 反应 115.0h， 生成 methyl 4-<<6-amino>indol-1-yl>methyl>-3-methoxybenzoate
  参考文献：
  名称：

  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles

  摘要：

  A perception of structural similarities between two independent series of leukotriene antagonists (one emanating from FPL 55712 and one based upon the leukotrienes themselves) led to the discovery of a novel class of indole and indazole derived antagonists of peptidoleukotrienes. A systematic exploration of C-6 substituted 4-(indol-1-ylmethyl)-3-methoxybenzoic acids identified cyclopentylacetamide and cyclopentylurethane as preferred substituents. The corresponding indazoles were equipotent. These compounds are selective leukotriene antagonists with pKB values of 7.5-7.8 vs LTE4 on guinea pig trachea.

  DOI：

  10.1021/jm00168a036

文献信息

• 1,3,6-Trisubstituted indoles as peptidoleukotriene antagonists: benefits of a second, polar, pyrrole substituent
  作者：Frederick J. Brown、Laura A. Cronk、David Aharony、David W. Snyder

  DOI：10.1021/jm00091a010

  日期：1992.6

  for asthma. Two new elements of structural diversity were introduced to this series of antagonists. An investigation of pyrrole substituents in the 1,6-substituted indoles demonstrated that substitution at C-2 was detrimental to biological activity, but the incorporation of hydrophilic groups at C-3 was beneficial. The introduction of a propionamide moiety at C-3 enhanced activity by 1 order of magnitude;

  含有酰基氨基和N-芳基磺酰基酰胺附件的1，6-取代的和3,5-取代的吲哚和吲唑是肽白三烯LTD4和LTE4的有效拮抗剂。3，5-取代的吲哚系列的化合物，N- [4-[[5-[[（环戊氧基）]]]甲基] [甲基] [3-基]甲基] -3-甲氧基苯甲酰基] -2-甲基-苯磺酰胺（ICI 204,219）正在接受哮喘的临床评估。该系列拮抗剂引入了结构多样性的两个新元素。对1，6-取代的吲哚中吡咯取代基的研究表明，C-2处的取代对生物活性有害，但在C-3处引入亲水基团是有益的。在C-3处引入丙酰胺部分将活性提高了1个数量级。N- [4-[[6-（环戊基乙酰胺基）-3-] [2-（N-甲基氨基甲酰基）乙基]吲哚-1-基]甲基] -3-甲氧基-苯甲酰基]苯磺酰胺（15c）的pKB为10.7豚鼠气管上的LTD4受体。二取代拮抗剂的酰基氨基部分的修饰表明酰胺CO和NH原子的转位是可行的。在1，6-和3，5
• Heterocyclic amides
  申请人：ICI AMERICAS INC.

  公开号：EP0179619A1

  公开（公告）日：1986-04-30

  The invention provides a series of novel heterocyclic amides of the formula I in which the group A∵CRa can be -CRb=CRa-, -CHRb-CHRa- or -N=CRa-, the amidic group Re.L can be Re.X.CO.NH, Re.X.CS.NH or Re.NH.CO attached at position 4, 5 or 6 of the benzenoid moiety, Z is an acid group selected from carboxy, an acylsulphonamide residue of the formula CO.NH.SOnRg and a tetrazolyl residue of the formula II, and the radicals Ra, Rb. Rc, Rd, Re, Rf, Rg, Rh, n, X, G', O and G2 have the meanings defined in the following specification. The compounds of formula 1 are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula 1 compounds, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.

  本发明提供了一系列式 I 的新型杂环酰胺，其中基团 A∵CRa 可以是 -CRb＝CRa-、-CHRb-CHRa- 或 -N＝CRa-，酰胺基团 Re.L 可以是 Re.X.CO.NH、Re.X.CS.NH 或 Re.NH.CO，连接在苯环基团的第 4、5 或 6 位，Z 是选自羧基、式 CO.NH.SOnRg 的酰基磺酰胺残基和 Z.NH 的酸基。Z 是选自羧基、式 CO.NH.SOnRg 的酰基磺酰胺残基和式 II 的四唑残基的酸基，自由基 Ra、Rb.Rc、Rd、Re、Rf、Rg、Rh、n、X、G'、O 和 G2 具有以下说明书中定义的含义。 式 1 的化合物是白三烯拮抗剂。本发明还提供了式 I 化合物的药学上可接受的盐；含有式 1 化合物或其盐的药物组合物，用于治疗例如过敏性或炎症性疾病，或内毒素性或创伤性休克病症；以及式 I 化合物的制造工艺和用于此类制造的中间体。
• BROWN, FREDERICK J.;YEE, YING K.;CRONK, LAURA A.;HEBBEL, KEVIN C.;KRELL, +, J. MED. CHEM., 33,(1990) N, C. 1771-1781
  作者：BROWN, FREDERICK J.、YEE, YING K.、CRONK, LAURA A.、HEBBEL, KEVIN C.、KRELL, +

  DOI：——

  日期：——
• US4997844A
  申请人：——

  公开号：US4997844A

  公开（公告）日：1991-03-05
• US5234942A
  申请人：——

  公开号：US5234942A

  公开（公告）日：1993-08-10